Healthcare
Tuesday, November 22, 2016
BRIEF-Immunovaccine's DPX-Survivac gets orphan drug designation by European medicines agency
* The european medicines agency grants orphan drug
designation status to Immunovaccine's DPX-Survivac in ovarian
cancer
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment